Thursday, June 4, 2026

#BIOTECH

17 articles

Eli Lilly Crosses $20B in 2026 Acquisitions as AI Rewrites Pharma's Global Deal Logic

Business & Finance

Eli Lilly Crosses $20B in 2026 Acquisitions as AI Rewrites Pharma's Global Deal Logic

Salvado•May 31, 2026

Global ADC Combination Race Peaks in 2026–2027, Compressing Binary Risk Across Three Continents

Biotech & Pharma

Global ADC Combination Race Peaks in 2026–2027, Compressing Binary Risk Across Three Continents

Salvado•May 27, 2026

Novo Nordisk Shares Surge 24.9% as Global Pharma Abandons Wet Labs for AI

Health & Science

Novo Nordisk Shares Surge 24.9% as Global Pharma Abandons Wet Labs for AI

Salvado•May 13, 2026

Global Biotech Valuations Rise as $120B Oncology Pipeline Targets 2026-2027 FDA Approvals

Global Biotech Valuations Rise as $120B Oncology Pipeline Targets 2026-2027 FDA Approvals

Salvado•Apr 18, 2026

U.S. Rare Disease Drugmaker Faces $200M Revenue Loss as Patent Cliff Looms in 2035

Healthcare & Pharmaceuticals

U.S. Rare Disease Drugmaker Faces $200M Revenue Loss as Patent Cliff Looms in 2035

ViaNews Editorial Team•Mar 12, 2026

Artiva Biotherapeutics faces $50-150M capital gap as NK cell therapy trials advance

Artiva Biotherapeutics faces $50-150M capital gap as NK cell therapy trials advance

ViaNews Editorial Team•Mar 7, 2026

Cardiff Oncology's $60M Cash Reserve Gives Five Quarters Before Funding Crisis

Cardiff Oncology's $60M Cash Reserve Gives Five Quarters Before Funding Crisis

ViaNews Editorial Team•Mar 7, 2026

Cardiff Oncology's $500M+ valuation at risk as cancer trial targeting 40-50% of colorectal cases nears Q1 2026 data release

Cardiff Oncology's $500M+ valuation at risk as cancer trial targeting 40-50% of colorectal cases nears Q1 2026 data release

ViaNews Editorial Team•Mar 7, 2026

Biotech Funding Drought Puts $300M Ophthalmology Drug at Risk of Capital Collapse

Biotech Funding Drought Puts $300M Ophthalmology Drug at Risk of Capital Collapse

ViaNews Editorial Team•Mar 1, 2026

Biotech Kyntra Bio Risks 60-80% Wipeout as Single Cancer Drug FG-3246 Faces Trial Verdict

pharmaceuticals

Biotech Kyntra Bio Risks 60-80% Wipeout as Single Cancer Drug FG-3246 Faces Trial Verdict

ViaNews Editorial Team•Feb 26, 2026

Zevra Therapeutics risks collapse as 90% revenue depends on single rare disease drug

Zevra Therapeutics risks collapse as 90% revenue depends on single rare disease drug

ViaNews Editorial Team•Feb 25, 2026

LeonaBio Risks $140M Market Cap on Single Breast Cancer Trial After Neurodegenerative Pivot

LeonaBio Risks $140M Market Cap on Single Breast Cancer Trial After Neurodegenerative Pivot

ViaNews Editorial Team•Feb 22, 2026

Biomerica's Cash Crisis Mirrors Global Biotech Funding Crunch

Healthcare & Biotech

Biomerica's Cash Crisis Mirrors Global Biotech Funding Crunch

ViaNews Editorial Team•Feb 21, 2026

NVIDIA's BioNeMo Positions AI as the New Global Lab Infrastructure in Race to Reinvent Drug Discovery

Science & Technology

NVIDIA's BioNeMo Positions AI as the New Global Lab Infrastructure in Race to Reinvent Drug Discovery

ViaNews Editorial Team•Feb 18, 2026

REGENXBIO's Duchenne Gene Therapy Targets 2027 Global Launch, Challenging Sarepta's Market Lead

Health & Biotech

REGENXBIO's Duchenne Gene Therapy Targets 2027 Global Launch, Challenging Sarepta's Market Lead

ViaNews Editorial Team•Feb 18, 2026

Cellectis Bets on Off-the-Shelf CAR-T Revolution as $700M Peak Sales Forecast Puts Global Cell Therapy Race in Focus

Health & Science

Cellectis Bets on Off-the-Shelf CAR-T Revolution as $700M Peak Sales Forecast Puts Global Cell Therapy Race in Focus

ViaNews Editorial Team•Feb 18, 2026

Four Major Drug Trials Hit Key Milestones in Early 2026, Signaling Productive Clinical Research Cycle

Four Major Drug Trials Hit Key Milestones in Early 2026, Signaling Productive Clinical Research Cycle

ViaNews Editorial Team•Feb 15, 2026